Company announcement

Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark. 5 November 2026 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney to publish the transactions on their behalf ..

Please find below a statement of such trading in shares issued by Novo Nordisk.

Novo Nordisk A/S
Investor Relations

Novo Alle 1
2880 Bagsværd
Denmark

Telephone:
+45 4444 8888

www.novonordisk.com
CVR no:24 25 67 90

1	**Details of the person discharging managerial responsibilities/person closely associated**	
a)	Name of the Board member/Executive/Associated Person	Martin Holst Lange
2	**Reason for the notification**	
a)	Position/status	Executive Vice President, R&D and Chief Scientific Officer (CSO)
b)	Initial notification/Amendment	Initial notification
3	**Details of the issuer**	
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	**Details of the transaction(s)**	
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333
b)	Nature of the transaction	Sale of shares
c)	Price(s) and volume(s)	Price(s): DKK 285.00 — Volume(s): 12,000
d)	Aggregated information • Aggregated volume • Price	 12,000 DKK 3,420,000.00
e)	Date of the transaction	2026-11-04
f)	Place of the transaction	Nasdaq Copenhagen

Novo is the global healthcare company that believes lasting health starts now. For over a century, we've combined leading scientific expertise with a deep understanding of people's lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 66,500 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we're working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo -B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube.

Contacts for further information

Novo Media:

Ambre James -Brown
+45 3079 9289
globalmedia@novonordisk.com

Liz Skrbkova (US)
+1 609 917 0632
USMediaRelations@novonordisk.com

Novo I nvestors:

Michael Novod
+45 3075 6050
nvno@novonordisk.com

Sina Meyer
+45 3079 6656
azey@novonordisk.com

Max Ung
+45 3077 6414
mxun@novonordisk.com

Christoffer Togo Solgaard -Tullin
+45 3079 1471
cftu@novonordisk.com

Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com

Mads Berner Bruun
+45 3075 2936
mbbz@novonordisk.com

Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com

Alex Bruce (US)
+1 640 230 0276
axeu@novonordisk.com